TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03538795

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: iTBS&eCIMT
Description: All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
Study: NCT03756701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind body skills
Description: 2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind body skills
Description: 2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual
Study: NCT02593019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date).
Study: NCT02756949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study: NCT03103828

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Tailored Intervention
Description: CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy
Description: Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
Study: NCT02406287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil (AR-13324) Ophthalmic Solution
Description: Topical ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Netarsudil (AR-13324) Ophthalmic Solution Placebo
Description: Ophthalmic solution once a day
Study: NCT02289820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510
Description: RSV sF antigen plus adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510
Description: RSV sF antigen plus adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510
Description: RSV sF antigen plus adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510
Description: RSV sF antigen plus adjuvant
Study: NCT00003927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT00130390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One nitazoxanide 500 mg tablet twice daily for 28 days
Study: NCT02289820

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV
Description: Marketed Inactivated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV
Description: Marketed Inactivated Influenza Vaccine
Study: NCT00808262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid at days 0, 7, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid at days 0, 7, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid at days 0, 7, 28
Study: NCT04583150

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
Study: NCT02651064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIP
Study: NCT03334045

Intervention type: RADIATION
Intervention: PET/MR scans
Description: Observations of glucose metabolism and dopamine binding potential
Study: NCT04454567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 tablets orally once daily
Study: NCT00707187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cialis
Description: 35 pills of study medication (20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cialis
Description: 35 pills of study medication (20 mg)
Study: NCT04232527

Intervention type: DIAGNOSTIC_TEST
Intervention: Y Balance Test
Description: The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sit and Reach Test
Description: This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximum Legs Abduction Test
Description: Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.

Intervention type: DIAGNOSTIC_TEST
Intervention: S_RAG (reactive agility) Test
Description: The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.

Intervention type: DIAGNOSTIC_TEST
Intervention: S_CODS (change of direction speed) Test
Description: S_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
Study: NCT03512249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: 5ug H56/500 nmol IC31

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for injection
Study: NCT03847974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIB003
Description: 300 mg SC Q4W
Study: NCT04366284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Facilitation Support
Description: Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
Study: NCT00003927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT04366284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Facilitation Support
Description: Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External and Internal Facilitation Support
Description: Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
Study: NCT00930033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nephrectomy
Description: Current surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunitinib alone
Description: Sunitinib alone without nephrectomy
Study: NCT05678517

Intervention type: DRUG
Intervention: Anti-VEGF
Description: intravitreal ranibizumab or intravitreal aflibercept
Study: NCT02346149

Intervention type: OTHER
Group type: OTHER
Intervention: glucose 20%
Description: Intravenous infusion (0.75 ml / kg) over 1 min
Study: NCT00935623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Challenge
Description: Malaria challenge

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Challenge
Description: Malaria challenge
Study: NCT00963430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
Study: NCT03028623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tubal ligation
Description: Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
Study: NCT04810533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] SH-1028
Description: Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
Study: NCT02169791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
Study: NCT04190706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioactive components fortified food products intake (biscuits and cookies)
Description: Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control food products intake (biscuits and cookies)
Description: Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
Study: NCT00130390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet twice daily for 28 days
Study: NCT02051387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00003927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01934881

Intervention type: DEVICE
Intervention: voltage adjustment only
Description: Only voltage will be adjusted in all programming sections.

Intervention type: DEVICE
Intervention: Multiple parameters adjustment
Description: More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
Study: NCT00235846

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vein harvest
Description: Conventional open vein harvest or endoscopic vein harvest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vein harvest
Description: Conventional open vein harvest or endoscopic vein harvest
Study: NCT02635776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR101 powder provided in capsules & sachets
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules & sachets
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study: NCT01021306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic w/Activator & Self Care
Description: This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Care & Self Care
Description: Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham AMCT
Description: This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-Care Only Group
Description: Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
Study: NCT02908451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-107
Description: Antibody Drug Conjugate
Study: NCT02623920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab
Description: Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04454567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 tablets orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo to ABI-H0731 tablets orally once daily
Study: NCT03582397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mirror Therapy
Description: Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
Study: NCT00844220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT/MR
Description: CT/MRI-directed clinical management strategy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization
Description: Standard clinical management directed by conventional coronary angiography
Study: NCT02180672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Fluticasone
Description: One spray per nostril, per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One spray per nostril, per day.
Study: NCT04454567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NrtI
Description: Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NrtI
Description: Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
Study: NCT01605331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sustained-release recombinant human GH (SR-rhGH)
Study: NCT01265667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12h
Study: NCT01120899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants take 100 mg minocycline pills twice daily for 24 months.
Study: NCT02625376

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resvega
Description: Dietary supplementation with Resvega BD

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-Resveratrol
Description: Dietary supplementation with resveratrol 250 mg BD

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dietary supplementation with a placebo BD